MedTrace Logo

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IV

NCT06642584 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2025-10-20

No results posted yet for this study

Summary

This study is conducted to compare four different tablets containing the investigational medicine semaglutide at the same dose. It is done to test how semaglutide in each of the tablet versions is taken up in the body. Which treatments participants will receive is decided by chance. The study will last for about 28 weeks. The study will enroll healthy male participants.

Conditions

  • Healthy Volunteers Type 2 Diabetes

Interventions

DRUG

Semaglutide B

Semaglutide B will be administered subcutaneously.

DRUG

Semaglutide J

Semaglutide J will be administered as oral tablets.

DRUG

Semaglutide L

Semaglutide L will be administered as oral tablets.

DRUG

Semaglutide M

Semaglutide M will be administered as oral tablets.

DRUG

Semaglutide N

Semaglutide N will be administered as oral tablets.

Sponsors & Collaborators

Principal Investigators

  • Clinical Transparency (dept. 2834) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-10-15
Primary Completion
2025-07-10
Completion
2025-08-13

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06642584 on ClinicalTrials.gov